IDT Australia Past Earnings Performance
Past criteria checks 0/6
IDT Australia's earnings have been declining at an average annual rate of -17%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been declining at an average rate of 8.6% per year.
Key information
-17.0%
Earnings growth rate
-14.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | -8.6% |
| Return on equity | -28.4% |
| Net Margin | -63.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
IDT Australia (ASX:IDT) Is Using Debt Safely
Apr 08
IDT Australia Limited's (ASX:IDT) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/E Ratio
Mar 04Here's Why Shareholders Will Not Be Complaining About IDT Australia Limited's (ASX:IDT) CEO Pay Packet
Nov 09IDT Australia's (ASX:IDT) Promising Earnings May Rest On Soft Foundations
Aug 31Is IDT Australia's (ASX:IDT) 280% Share Price Increase Well Justified?
Mar 20IDT Australia (ASX:IDT) Is In A Good Position To Deliver On Growth Plans
Jan 13Does IDT Australia's (ASX:IDT) CEO Salary Compare Well With The Performance Of The Company?
Dec 09
Revenue & Expenses BreakdownBeta
How IDT Australia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10 | -7 | 9 | 0 |
| 30 Sep 23 | 9 | -8 | 9 | 0 |
| 30 Jun 23 | 7 | -8 | 8 | 0 |
| 31 Mar 23 | 7 | -8 | 7 | 0 |
| 31 Dec 22 | 6 | -8 | 7 | 0 |
| 30 Sep 22 | 9 | -5 | 7 | 0 |
| 30 Jun 22 | 12 | -1 | 7 | 0 |
| 31 Mar 22 | 16 | 1 | 7 | 0 |
| 31 Dec 21 | 21 | 2 | 7 | 0 |
| 30 Sep 21 | 19 | 2 | 7 | 0 |
| 30 Jun 21 | 17 | 2 | 7 | 0 |
| 31 Mar 21 | 14 | 1 | 7 | 0 |
| 31 Dec 20 | 12 | 0 | 7 | 0 |
| 30 Sep 20 | 13 | -1 | 7 | 0 |
| 30 Jun 20 | 14 | -2 | 7 | 0 |
| 31 Mar 20 | 13 | -3 | 7 | 0 |
| 31 Dec 19 | 13 | -5 | 7 | 0 |
| 30 Sep 19 | 12 | -5 | 8 | 0 |
| 30 Jun 19 | 12 | -6 | 8 | 0 |
| 31 Mar 19 | 13 | -4 | 8 | 0 |
| 31 Dec 18 | 15 | -2 | 8 | 0 |
| 30 Sep 18 | 14 | -10 | 8 | 0 |
| 30 Jun 18 | 13 | -17 | 8 | 0 |
| 31 Dec 17 | 10 | -29 | 9 | 0 |
| 30 Sep 17 | 10 | -22 | 9 | 0 |
| 30 Jun 17 | 10 | -15 | 10 | 0 |
| 31 Dec 16 | 9 | -4 | 9 | 0 |
| 30 Sep 16 | 9 | -4 | 9 | 0 |
| 30 Jun 16 | 8 | -4 | 8 | 0 |
| 31 Mar 16 | 10 | -4 | 8 | 1 |
| 31 Dec 15 | 13 | -3 | 8 | 3 |
| 30 Sep 15 | 14 | -3 | 9 | 3 |
| 30 Jun 15 | 16 | -3 | 10 | 3 |
| 31 Mar 15 | 13 | -5 | 11 | 1 |
| 31 Dec 14 | 11 | -8 | 11 | 0 |
| 30 Sep 14 | 12 | -7 | 12 | 0 |
| 30 Jun 14 | 13 | -7 | 13 | 0 |
| 31 Mar 14 | 15 | -7 | 13 | 0 |
| 31 Dec 13 | 17 | -7 | 13 | 0 |
| 30 Sep 13 | 15 | -6 | 11 | 0 |
| 30 Jun 13 | 13 | -5 | 9 | 0 |
Quality Earnings: IDT is currently unprofitable.
Growing Profit Margin: IDT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IDT is unprofitable, and losses have increased over the past 5 years at a rate of 17% per year.
Accelerating Growth: Unable to compare IDT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IDT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16%).
Return on Equity
High ROE: IDT has a negative Return on Equity (-28.38%), as it is currently unprofitable.